Group items tagged

Baby teeth could one day lead to the development of a much-needed tool for identifying children who are at risk for psychological problems, a study by the University of Bristol has concluded. The research has been published in the 'JAMA Network Open' - a monthly journal published by the American Medical Association. The origin of this study traces back several years, when senior author Erin Dunn - a social and psychiatric epidemiologist and an investigator in MGH's Psychiatric and Neurodevelopmental Genetics Unit - learned about work in the field of anthropology that could help solve a longstanding problem in her own research. She studies the effects of childhood adversity, which research suggested, is responsible for up to one-third of all mental health disorders. Dunn is particularly interested in the timing of these adverse events and in uncovering whether there are sensitive periods during child development when exposure to adversity is particularly harmful.

bodivis Fat Analysis Monitor Machine, Eight-Electrode BCA-1A Bioelectrical Impedance Analysis Cost bodivis Eight-Electrode Biospace Body Composition Analyzer BCA-1A Types of body fat checker machines There are some main styles of body fat monitors on the market today-scales, handheld devices, and Dual-Energy X-ray Absorptiometry (DXA) and skinfold calipers. Estimating body fat percentage with skinfold calipers is affordable and relatively simple once you know how to do it. However, the accuracy depends on the skill of the person performing the assessment.

The General Pharmaceutical Council (GPhC) has revealed it has received 25 whistleblowing disclosures between April 2021 and March 2022. The pharmacy regulator said, in its annual report, that it has concluded enquiries on 22 disclosures so far with a further three still under review. "We also concluded two qualifying disclosures that were raised during the previous reporting period," it said, adding: "The action GPhC took included a full investigation through established fitness to practise processes and follow-up action through its inspection network. "The former can result in any available outcome throughout the fitness to practise process. The latter can include guidance, a follow-up visit or an unexpected inspection." 12 concerns were investigated and concluded with no further action. Three were signposted to another organisation. The remaining seven cases were concluded by sharing information with inspection colleagues for follow up action. Of the two concerns from the previous reporting period, one was concluded with no further action and the other remains under investigation.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK. A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients. Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older. The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.

Leading pharmacy group Weldricks has strengthened its commitment to providing the highest quality of care to the communities it serves by implementing the RPS Daffodil Quality Improvement Standards for Community Pharmacy. The Royal Pharmaceutical Society (RPS) on Monday (20 November) announced that Weldricks will soon be rolling out the Daffodil Standards across half its stores in South Yorkshire. Developed in partnership with UK charity Marie Curie, the RPS Daffodil Standards serve as a framework for improving the quality of palliative and end-of-life care provided by community pharmacy teams. Amy Marlin, Superintendent Pharmacist of Weldricks, commented that the implementation of the RPS Daffodil Standards is "another step forward in our journey to provide the highest quality of care to the communities we serve."

The Royal Pharmaceutical Society (RPS) on Wednesday (14 February) launched consultations on two new pioneer curricula defining the clinical capabilities expected of entry-level advanced pharmacists practising in critical care and mental health. The advanced pharmacist critical care curriculum and the advanced pharmacist mental health curriculum are supplementary to the RPS core advanced curriculum. Interested stakeholders are invited to provide feedback on the content of the curricula, their feasibility in terms of delivery, their relevance to all countries, and how these may impact different social groups. Both consultations will be open until Tuesday 12 March, and members and non-members of RPS can submit their comments via the online form or the word document.